$135.90
-1.03[-0.75%]
At close: Apr 26
$135.90
0[0.00%]
After Hours: 4:00PM EDT
Ascendis Pharma
(NASDAQ:ASND)Latest News for Ascendis Pharma Stock (NASDAQ:ASND)
Ascendis Pharma Stock (NASDAQ: ASND)
Categories: All
Friday, April 26, 2024
Wednesday, April 24, 2024
Monday, April 22, 2024
Thursday, April 18, 2024
Friday, April 12, 2024
Wednesday, April 03, 2024
Tuesday, April 02, 2024
Monday, April 01, 2024
Friday, March 15, 2024
Thursday, March 14, 2024
Sunday, March 03, 2024
Friday, February 23, 2024
Tuesday, February 13, 2024
Thursday, February 08, 2024
- If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 TodayBenzinga Insights - Feb 8, 2024, 11:30AM
- Citigroup Maintains Buy on Ascendis Pharma, Raises Price Target to $182Benzinga Newsdesk - Feb 8, 2024, 11:07AM
- Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $225Benzinga Newsdesk - Feb 8, 2024, 8:27AM
Wednesday, February 07, 2024
Tuesday, February 06, 2024
Friday, February 02, 2024
Monday, January 29, 2024
Monday, January 08, 2024
- Er-Kim Announces Exclusive Distribution Agreement With Ascendis Pharma A/S To Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe And TurkeyBenzinga Newsdesk - Jan 8, 2024, 10:58PM
- Vector Pharma FZCO Enters Exclusive Distribution Agreement With Ascendis Pharma To Commercialize Skytrofa And Yorvipath In Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar And BahrainBenzinga Newsdesk - Jan 8, 2024, 8:21AM
Sunday, January 07, 2024
- Ascendis Pharma Introduces Vision 2030; Preliminary Unaudited December 31, 2023 Cash, Cash Equivalents, And Marketable Securities Of ~€400M; Full Year 2024 SKYTROFA Revenue Expected To Be €320M-€340MBenzinga Newsdesk - Jan 7, 2024, 8:16PM
- Specialised Therapeutics Signs Exclusive Agreement With Ascendis Pharma For Distribution And Commercialization Of Three Endocrinology Therapies In Australia And Select South-East Asia CountriesCharles Gross - Jan 7, 2024, 2:34PM
Wednesday, December 20, 2023
- Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price TargetBenzinga Newsdesk - Dec 20, 2023, 10:27AM
- Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $202Benzinga Newsdesk - Dec 20, 2023, 8:58AM
- Ascendis Pharma Announces Significant Health And Quality Of Life Improvements Achieved In Children With Achondroplasia Treated For One Year With TransCon CNP At 100 µg/kg/weekBenzinga Newsdesk - Dec 20, 2023, 8:35AM
- Jefferies Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $150Benzinga Newsdesk - Dec 20, 2023, 6:37AM
Tuesday, December 19, 2023
- Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 TrialVandana Singh - Dec 19, 2023, 2:30PM
- Ascendis Pharma Announces Topline Results From TransCon hGH Achieved Statistically Superior Outcomes Compared To Placebo In Phase 3 foresiGHt Trial Of Adults With Growth Hormone DeficiencyBenzinga Newsdesk - Dec 19, 2023, 8:35AM
- Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $149Benzinga Newsdesk - Dec 19, 2023, 8:23AM
Monday, December 11, 2023
Wednesday, November 29, 2023
- Ascendis Pharma shares are trading higher after the company entered into an exclusive license agreement with Teijin Limited for Japan rights to rare disease drugs.Benzinga Newsdesk - Nov 29, 2023, 12:27PM
- Ascendis Pharma Strikes $70M Deal with Teijin for Japan Rights to Rare Disease Drugs, Securing Up to $175M Plus Royalties for Endocrinology DrugsBenzinga Newsdesk - Nov 29, 2023, 4:35AM